Often seen as an option of last resort for ventricular tachycardia, new research suggests catheter ablation could have a ...

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, ...

Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment ...

Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

The lack of effect on QoL and oxygen consumption help cement the idea that the disease isn’t the same as obstructive HCM.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...